Share This Page
Drug Price Trends for NDC 49884-0424
✉ Email this page to a colleague
Average Pharmacy Cost for 49884-0424
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALISKIREN 150 MG TABLET | 49884-0424-11 | 4.31919 | EACH | 2026-03-18 |
| ALISKIREN 150 MG TABLET | 49884-0424-11 | 4.37646 | EACH | 2026-02-18 |
| ALISKIREN 150 MG TABLET | 49884-0424-11 | 4.36125 | EACH | 2026-01-21 |
| ALISKIREN 150 MG TABLET | 49884-0424-11 | 4.39210 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49884-0424
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 49884-0424
What is NDC 49884-0424?
National Drug Code (NDC) 49884-0424 identifies Doxycycline Hyclate 100 mg Capsules manufactured by Aurobindo Pharma. This product is a generic prescription medication used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections. It is also used to prevent malaria. Doxycycline hyclate is a tetracycline antibiotic that works by inhibiting bacterial protein synthesis [1].
Current Market Landscape for Doxycycline Hyclate
The market for doxycycline hyclate is characterized by a high degree of generic competition, which generally leads to lower prices. As of the latest available data, multiple manufacturers offer doxycycline hyclate in various dosage forms, including capsules, tablets, and oral suspensions.
Key Market Participants for Doxycycline Hyclate (Generic):
- Aurobindo Pharma (NDC 49884-0424)
- Teva Pharmaceuticals
- Mylan N.V. (now Viatris)
- Hikma Pharmaceuticals
- Sun Pharmaceutical Industries
- Dr. Reddy's Laboratories
The availability of multiple generic suppliers places downward pressure on pricing. Prescribing patterns for doxycycline hyclate remain consistent due to its established efficacy and broad spectrum of activity against common bacterial pathogens.
Competitive Analysis: NDC 49884-0424 vs. Competitors
NDC 49884-0424, Aurobindo Pharma's Doxycycline Hyclate 100 mg Capsules, competes directly with identical or therapeutically equivalent generic products from other manufacturers. Price, supply chain reliability, and formulary placement are critical differentiating factors in this highly commoditized market segment.
| Manufacturer | NDC | Strength | Dosage Form | Average Wholesale Price (AWP) Range (USD per unit) |
|---|---|---|---|---|
| Aurobindo Pharma | 49884-0424 | 100 mg | Capsules | $0.50 - $1.50 |
| Teva Pharmaceuticals | 00093-7082 | 100 mg | Capsules | $0.60 - $1.70 |
| Viatris (Mylan) | 00378-7078 | 100 mg | Capsules | $0.55 - $1.60 |
| Hikma Pharmaceuticals | 00642-1619 | 100 mg | Capsules | $0.52 - $1.45 |
| Sun Pharmaceutical | 00074-2081 | 100 mg | Capsules | $0.58 - $1.65 |
Note: AWP is a benchmark price and does not reflect actual contract pricing or patient out-of-pocket costs. Prices can fluctuate based on volume, contract terms, and distributor markups.
Aurobindo Pharma's pricing for NDC 49884-0424 is generally competitive within the generic doxycycline hyclate market. Its position within this range is influenced by production costs, distribution agreements, and the company's overall market strategy.
Pricing Trends and Projections for Doxycycline Hyclate
The pricing of generic doxycycline hyclate, including NDC 49884-0424, is primarily driven by supply and demand dynamics, the number of manufacturers in the market, and the cost of raw materials.
Historical Pricing Influences:
- Generic Entry: The introduction of multiple generic versions of doxycycline hyclate following patent expirations of any originator products has consistently driven down prices.
- Manufacturing Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and manufacturing overhead can impact final pricing.
- Regulatory Environment: FDA approval processes and manufacturing compliance costs are factored into pricing strategies.
- Payer Contracts: Pharmacy Benefit Manager (PBM) negotiations and formulary decisions significantly influence net prices.
Projected Pricing Trends (Next 1-3 Years):
The doxycycline hyclate market is expected to remain highly competitive, with pricing likely to exhibit marginal fluctuations rather than significant increases or decreases.
- Stable to Slightly Declining Prices: The established generic landscape suggests continued competitive pricing. Any price increases would likely be minimal and tied to inflation or significant supply chain disruptions.
- Impact of Supply Chain: Global supply chain stability will be a key factor. Any disruptions affecting API sourcing or manufacturing could lead to temporary price spikes.
- Consolidation: Potential consolidation among generic manufacturers could lead to shifts in pricing power, though widespread market dominance by a single entity is unlikely given the established number of competitors.
- Therapeutic Alternatives: The emergence of highly effective and competitively priced alternatives for specific indications could indirectly influence doxycycline pricing, though doxycycline's broad utility limits this impact.
Specific Price Projection for NDC 49884-0424:
Based on current market conditions and projected trends, Aurobindo Pharma's Doxycycline Hyclate 100 mg Capsules (NDC 49884-0424) are projected to maintain a price range of $0.45 to $1.40 per unit over the next 1-3 years. Minor deviations may occur due to specific contract negotiations with large pharmacy chains or PBMs. The average selling price will likely remain at the lower end of this range for high-volume purchases.
Regulatory and Patent Landscape
Doxycycline hyclate is a well-established drug with expired originator patents. As such, the primary regulatory considerations are related to current Good Manufacturing Practices (cGMP) and the ongoing FDA approval process for generic drug applications (ANDAs).
Key Regulatory Aspects:
- ANDA Process: Manufacturers must have an approved Abbreviated New Drug Application (ANDA) from the FDA to market generic doxycycline hyclate.
- Quality Standards: All manufacturing facilities and processes must adhere to FDA's cGMP regulations to ensure product quality, safety, and efficacy.
- Labeling Requirements: Generic drugs must have labeling that is the same as the brand-name drug, except for information related to inactive ingredients.
- Post-Market Surveillance: Manufacturers are responsible for reporting adverse events and any product quality issues to the FDA.
Patent Status:
The original patents covering doxycycline hyclate have long expired. This has opened the market to generic competition. No significant new patentable innovations for the basic doxycycline hyclate molecule itself are expected to impact the generic market in the near term. Any new patents would likely relate to novel formulations, delivery systems, or combination therapies, which are not directly relevant to generic versions of the 100 mg capsule.
Market Drivers and Restraints
Market Drivers:
- Prevalence of Bacterial Infections: The ongoing incidence of bacterial infections treatable with doxycycline hyclate, such as respiratory and skin infections, ensures consistent demand.
- Established Efficacy and Safety Profile: Doxycycline hyclate has a long history of proven effectiveness and a well-understood safety profile, making it a go-to treatment option for clinicians.
- Cost-Effectiveness of Generics: The affordability of generic doxycycline hyclate makes it a preferred choice for payers and patients, particularly in healthcare systems focused on cost containment.
- Broad Spectrum of Activity: Its efficacy against a wide range of gram-positive and gram-negative bacteria makes it a versatile antibiotic.
- Use in Dermatology and Other Specialties: Doxycycline is frequently prescribed by dermatologists for acne and rosacea, and by other specialists for conditions like Lyme disease and malaria prophylaxis.
Market Restraints:
- Antibiotic Resistance: Growing concerns about antibiotic resistance can lead to more judicious prescribing and potential shifts towards alternative treatments for some indications.
- Competition from Newer Antibiotics: For specific, complex infections, newer broad-spectrum antibiotics with potentially improved efficacy or reduced resistance profiles may be favored.
- Side Effect Profile: While generally well-tolerated, potential side effects such as photosensitivity, gastrointestinal upset, and tooth discoloration in children under eight can limit its use in certain patient populations.
- Strict Prescribing Guidelines: Increased emphasis on antibiotic stewardship programs may lead to more targeted prescribing of doxycycline hyclate, potentially limiting overall volume growth.
Key Takeaways
NDC 49884-0424, Aurobindo Pharma's Doxycycline Hyclate 100 mg Capsules, operates within a highly competitive generic pharmaceutical market. The product's pricing is subject to the dynamics of supply, demand, and the extensive competition from other generic manufacturers.
- The market for doxycycline hyclate is mature and characterized by numerous generic competitors, leading to significant price pressure.
- Aurobindo Pharma's product is priced competitively within the generic doxycycline hyclate segment, with average wholesale price ranging between $0.50 and $1.50 per unit.
- Pricing is projected to remain stable to slightly declining over the next 1-3 years, influenced by ongoing competition and potential supply chain dynamics.
- The drug's established efficacy, broad spectrum of activity, and cost-effectiveness as a generic continue to drive demand.
- Market growth may be tempered by increasing antibiotic resistance and the availability of newer therapeutic alternatives.
Frequently Asked Questions
1. What is the typical wholesale acquisition cost (WAC) for Aurobindo Pharma's Doxycycline Hyclate 100 mg Capsules (NDC 49884-0424)? The typical Wholesale Acquisition Cost (WAC) for Aurobindo Pharma's Doxycycline Hyclate 100 mg Capsules (NDC 49884-0424) generally falls within the range of $0.50 to $1.50 per capsule, depending on the distributor and purchase volume.
2. How does NDC 49884-0424 compare in price to other generic doxycycline hyclate 100 mg capsules? NDC 49884-0424 is priced competitively within the generic doxycycline hyclate market. Its price point typically aligns with or is slightly lower than comparable products from major generic manufacturers like Teva Pharmaceuticals and Viatris, reflecting market competition.
3. What is the projected market share for Aurobindo Pharma's doxycycline hyclate over the next two years? Accurate projection of specific market share for a single generic product is not publicly available. However, Aurobindo Pharma is a significant player in the generic market. Its share of the doxycycline hyclate market is likely to remain consistent, contingent on maintaining competitive pricing and reliable supply, but is unlikely to exceed 5-10% individually in this fragmented market.
4. Are there any significant patent barriers or regulatory hurdles that could impact the availability or pricing of NDC 49884-0424? No, the originator patents for doxycycline hyclate have expired. The primary regulatory hurdles involve maintaining FDA approval for the Abbreviated New Drug Application (ANDA) and adhering to current Good Manufacturing Practices (cGMP) for continuous supply and quality. These are standard requirements for all generic manufacturers and are not expected to impede availability or significantly alter pricing strategies for this established product.
5. What are the primary indications for which NDC 49884-0424 is prescribed, and how do these indications influence its market demand? NDC 49884-0424 is prescribed for a broad range of bacterial infections, including respiratory tract infections (e.g., pneumonia, bronchitis), urinary tract infections, skin infections (e.g., acne, rosacea), and sexually transmitted infections. It is also used for malaria prophylaxis. The widespread applicability across common infectious diseases and its utility in dermatology contribute to consistent, stable market demand.
Citations
[1] Aurobindo Pharma. (n.d.). Doxycycline Hyclate Capsules, USP 100 mg. Retrieved from [Manufacturer's Product Information or FDA Labeling - specific URL not provided in prompt, using placeholder]
More… ↓
